Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SELE | P16581 | 7/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16004512 | 0.87 | MAPK1 (0.37) | MAPK1HSD17B10SELEVCAM1ALDH1A1 | |
| SCHEMBL2756710 | 0.82 | MAPK1 (0.34) | MAPK1HSD17B10SELEVCAM1ALDH1A1 | |
| SCHEMBL23794121 | 0.82 | MAPK1 (0.38) | MAPK1HSD17B10SELEVCAM1ALDH1A1 | |
| SCHEMBL12651908 | 0.80 | CYP1A2 (0.36) | MAPK1HSD17B10SELEVCAM1ALDH1A1 | |
| SCHEMBL9980132 | 0.80 | MAPK1 (0.39) | MAPK1HSD17B10SELEVCAM1ALDH1A1 | |
| SCHEMBL21608640 | 0.80 | MAPK1 (0.37) | MAPK1HSD17B10CA2 | |
| SCHEMBL13407339 | 0.80 | MAPK1 (0.33) | MAPK1HSD17B10SELEVCAM1GAA | |
| SCHEMBL14985734 | 0.78 | MAPK1 (0.33) | MAPK1HSD17B10 | |
| SCHEMBL11892113 | 0.78 | GPR35 (0.42) | MAPK1HSD17B10SELEVCAM1ALDH1A1 | |
| SCHEMBL2756691 | 0.76 | IKBKB (0.41) | SELEVCAM1GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567425-B2 | Periodic structured organic films | XEROX CORPORATION (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170022338-A1 | PERIODIC STRUCTURED ORGANIC FILMS | XEROX CORPORATION | 2017-01-26 | — | — | US | disclosed |
| US-20160259256-A1 | IMAGING MEMBERS COMPRISING CAPPED STRUCTURED ORGANIC FILM COMPOSITIONS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2016-09-08 | — | — | US | disclosed |
| US-9097995-B2 | Electronic devices comprising structured organic films | XEROX CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| US-8859171-B2 | Charge transport particles | XEROX CORPORATION (US) | 2014-10-14 | — | — | US | disclosed |
| US-8759473-B2 | High mobility periodic structured organic films | XEROX CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2014026244-A1 | PHOTOACTIVE OPTOELECTRONIC AND TRANSISTOR DEVICES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2014-02-20 | — | — | WO | disclosed |
| US-20130137033-A1 | PROCESS FOR PREPARING STRUCTURED ORGANIC FILMS (SOFS) VIA A PRE-SOF | XEROX CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-8394495-B2 | Composite structured organic films | XEROX CORPORATION (US) | 2013-03-12 | — | — | US | disclosed |
| US-8389060-B2 | Process for preparing structured organic films (SOFs) via a pre-SOF | XEROX CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8093347-B2 | Structured organic films | XEROX CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110217642-A1 | CHARGE TRANSPORT PARTICLES | XEROX CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100227071-A1 | PROCESS FOR PREPARING STRUCTURED ORGANIC FILMS (SOFS) VIA A PRE-SOF | XEROX CORPORATION (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227157-A1 | COMPOSITE STRUCTURED ORGANIC FILMS | XEROX CORPORATION (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227998-A1 | STRUCTURED ORGANIC FILMS | XEROX CORPORATION (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227081-A1 | MIXED SOLVENT PROCESS FOR PREPARING STRUCTURED ORGANIC FILMS | XEROX CORPORATION (US) | 2010-09-09 | — | — | US | disclosed |
| US-7718760-B2 | π-Conjugated polymer and manufacturing method thereof | RICOH COMPANY, LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7611823-B1 | Photosensitive polymeric material for WORM optical data storage with two-photon fluorescent readout | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MAPK1 3854/4885HSD17B10 3314/4885SELE 3219/4885 |
| US-20100227998-A1 | STRUCTURED ORGANIC FILMS | VIM, PUF60, EPCAM | MAPK1 4389/4885HSD17B10 3909/4885SELE 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.